|
2024 Conference Publication Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisKhoo, E., Amiss, A., Ding, J. N., Bryant, R., Mohsen, W., Connor, S., Leung, R., Croft, A., Lynch, K., Sparrow, M., De Cruz, P., An, Y. K., Holtmann, G. and Begun, J. (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0984 |
|
2024 Conference Publication Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to TofacitinibGilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194 |
|
2024 Conference Publication Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trialDavies, J., Amiss, A., Khoo, E., An, Y. K. and Begun, J. (2024). Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0164 |
|
2024 Conference Publication Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyKim, D. H., Park, S. H., Kim, H. S., Kim, S. J., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0555 |
|
2024 Journal Article Cannabidiol - help and hype in targeting mucosal diseasesMoniruzzaman, Md, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2024). Cannabidiol - help and hype in targeting mucosal diseases. Journal of Controlled Release, 365, 530-543. doi: 10.1016/j.jconrel.2023.11.010 |
|
2024 Conference Publication A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfactionFernandes, R., Khoo, E., Harris, H., Gilmore, R., Khaing, M., Begun, J., An, Y. K. and Mater IBD Research Group (2024). A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0750 |
|
2024 Conference Publication Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyKim, S. J., Kim, D. H., Park, S. H., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0892 |
|
2023 Journal Article Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatmentKhoo, Emi, Lee, Andrew, Neeman, Teresa, An, Yoon‐Kyo and Begun, Jakob (2023). Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment. JGH Open, 7 (12), 899-907. doi: 10.1002/jgh3.13000 |
|
2023 Journal Article Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction studyPeyrin-Biroulet, Laurent, Allegretti, Jessica R., Rubin, David T., Bressler, Brian, Germinaro, Matthew, Huang, Kuan-Hsiang (Gary), Shipitofsky, Nicole, Zhang, Hongyan, Wilson, Rebbecca, Han, Chenglong, Feagan, Brian G., Sandborn, William J., Panés, Julian, Hisamatsu, Tadakazu, Lichtenstein, Gary R., Sands, Bruce E., Dignass, Axel, Abrahamovych, Orest, Afanasieva, Halyna, Aitova, Lilia, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Augustyn, Monika, Balestrieri, Paola, Begun, Jakob, Brunatto, Luciana, Bulgheroni, Diego ... QUASAR Study Group (2023). Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology, 165 (6), 1443-1457. doi: 10.1053/j.gastro.2023.08.038 |
|
2023 Journal Article Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epitheliaMann, Zoya, Lim, Fayth, Verma, Suzie, Nanavati, Bageshri N., Davies, Julie M., Begun, Jakob, Hardeman, Edna C., Gunning, Peter W., Subramanyam, Deepa, Yap, Alpha S. and Duszyc, Kinga (2023). Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epithelia. Molecular Biology of the Cell, 35 (1) br3, 1-12. doi: 10.1091/mbc.e23-08-0337 |
|
2023 Conference Publication Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experienceGilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Journal Article MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrierMcGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011 |
|
2023 Conference Publication Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experienceTan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights programMcnamara, J., Ghaly, S., Pipicella, J., Wilson, W., Goodfellow, T., Cheema, M., Lynch, K., Williams, A., Begun, J., Gearry, R., Kim, A., Haifer, C., Forbes, A., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Andrews, J. and Connor, S. (2023). Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY. |
|
2023 Conference Publication The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portalMcnamara, J., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Wark, G., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Brett, L., Verdon, C., Andrews, J. and Connor, S. (2023). The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portal. HOBOKEN: WILEY. |
|
2023 Conference Publication Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS)Choi, R. C-H, Pudipeddi, A., Lin, H., Paramsothy, S., Ghaly, S., Begun, J., Kariyawasam, V., Yau, Y., Fung, C. and Leong, R. (2023). Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS). HOBOKEN: WILEY. |
|
2023 Conference Publication Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitisRice, K., Fernandes, R., Hendy, P., Khoo, E., Walker, N., Howlett, M., An, Y-K and Begun, J. (2023). Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication From enemies to friends: Exploring the capacity of novel compounds secreted by "pathobiont" gut bacteria to attenuate inflammation in inflammatory bowel diseaseReed, H., Sehgal, A., Morrison, M. and Begun, J. (2023). From enemies to friends: Exploring the capacity of novel compounds secreted by "pathobiont" gut bacteria to attenuate inflammation in inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDCFernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Moore, G., Gazelakis, K., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Judge, C., Ngoi, B., Lynch, K., Begun, J. and An, Y-K (2023). Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel diseaseTan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
